(NASDAQ: ARCT) Arcturus Therapeutics Holdings's forecast annual revenue growth rate of 77.03% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Arcturus Therapeutics Holdings's revenue in 2024 is $166,799,000.On average, 3 Wall Street analysts forecast ARCT's revenue for 2024 to be $5,015,009,567, with the lowest ARCT revenue forecast at $3,015,045,521, and the highest ARCT revenue forecast at $7,898,547,211. On average, 3 Wall Street analysts forecast ARCT's revenue for 2025 to be $10,414,745,618, with the lowest ARCT revenue forecast at $4,506,149,983, and the highest ARCT revenue forecast at $20,752,190,658.
In 2026, ARCT is forecast to generate $27,634,149,141 in revenue, with the lowest revenue forecast at $3,750,369,960 and the highest revenue forecast at $51,517,928,321.